<DOC>
	<DOCNO>NCT00387959</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , cyclophosphamide fludarabine , total-body irradiation , rituximab donor umbilical cord blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well give chemotherapy radiation therapy together rituximab umbilical cord blood transplant work treat patient B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Chemotherapy , Radiation Therapy , Rituximab , Umbilical Cord Blood Transplant Treating Patients With B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall event-free survival 1 year patient B-cell lymphoid malignancy treat nonmyeloablative conditioning regimen , rituximab , umbilical cord blood ( UCB ) transplantation ( UCBT ) . Secondary - Determine speed neutrophil platelet recovery post allograft patient . - Determine incidence speed donor-derived engraftment contribution UCB unit engraftment patient . - Determine incidence severity acute graft-vs-host disease ( GVHD ) 100 day patient . - Determine incidence severity chronic GVHD 1 year patient . - Determine incidence serious infectious complication correlate laboratory measurement immune recovery patient . - Determine response vaccination UCBT patient . - Determine incidence treatment-related mortality 100 day 180 day patient . - Determine incidence malignant relapse disease progression 1 2 year patient . - Determine probability overall event-free survival 2 year UCBT patient . - Determine performance laboratory study investigate double-unit biology correlate unit engraftment patient . OUTLINE : - Pre-transplant rituximab therapy : Patients receive rituximab IV day -8 -7 day -4 . - Nonmyeloablative conditioning regimen : Patients receive fludarabine phosphate IV 30 minute day -6 -2 cyclophosphamide IV day -6 . Patients also undergo total-body irradiation day -1 . - Umbilical cord blood transplantation : Patients undergo umbilical cord blood transplantation day 0 . Patients receive filgrastim ( G-CSF ) IV subcutaneously begin day 7 continue blood count recover . - Post-transplant rituximab therapy : Patients receive rituximab IV day 7 , 14 , 21 , 28 . - Graft-vs-host disease prophylaxis : Patients receive cyclosporine IV 2-4 hour orally twice daily day -3 100 , follow taper . Patients also receive mycophenolate mofetil IV orally three time daily day -3 45 , follow taper . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : CD20+* aggressive Bcell nonHodgkin 's lymphoma ( NHL ) , include 1 following : Diffuse large cell ( DLC ) NHL meet 1 follow criterion : Relapsed disease initial therapy fail mobilize bone marrow involvement therefore suitable autologous stem cell transplantation Highintermediate highrisk , secondline , ageadjusted International Prognostic Index ( IPI ) score second complete remission ( CR ) partial remission ( PR ) prior autologous stem cell transplantation Failed prior autologous stem cell transplantation least PR salvage chemotherapy Large cell transformation indolent NHL/chronic lymphocytic leukemia ( CLL ) meeting follow criterion : CR/PR large cell component disease salvage chemotherapy autologous stem cell transplantation Mantle cell lymphoma meet 1 follow criterion : Highrisk , define p53 positivity first CR/PR initial therapy Relapsed disease initial therapy second third CR/PR salvage chemotherapy CD20+* indolent NHL CLL meeting follow criterion : Must second subsequent progression ( preallograft cytoreduction necessary CR/PR require ) Indolent NHL include , limited , follow : Follicular NHL Small cell NHL Marginal zone NHL NOTE : *CD20 positivity must demonstrate within past 12 month Relapsed disease must biopsy proven Prior preallograft cytoreduction may include 1 follow : Single autologous stem cell transplantation highdose chemotherapy conditioning , appropriate , condition prior transplantation Two course intensive combination chemotherapy ( e.g. , rituximab , irinotecan hydrochloride , cetuximab , epirubicin hydrochloride [ RICE ] ) appropriate accord diagnosis prior therapy Heavily pretreated CLL patient combination chemotherapy appropriate may receive singleagent intermediatedose cyclophosphamide 23 course No mantle cell DLC NHL progressive disease allograft workup No suitable match related unrelated donor available Two umbilical cord blood ( UCB ) unit available meeting follow criterion : Units recipient must ≥ 4/6 HLAA B antigen DRB1 allele match Each unit must ≥ 1.5 x 10^7 total nucleated cells/recipient body weight PATIENT CHARACTERISTICS : Karnofsky performance score 70100 % Creatinine clearance ≥ 50 mL/min Bilirubin &lt; 2.5 mg/dL AST ALT ≤ 3 time upper limit normal ( unless due benign congenital hyperbilirubinemia ) Spirometry correct DLCO ≥ 50 % normal LVEF ≥ 40 % Albumin ≥ 2.5 g/dL No active uncontrolled infection time transplantation , include active infection Aspergillus mold No HIV positivity Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No 120 day since prior autologous stem cell transplantation No 60 day since prior chemotherapy No prior allogeneic transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
</DOC>